Abstracts tagged "Sjögren’s syndrome"

Abstract Number: 1409 • ACR Convergence 2024
Salivary Organoids Contain More Diverse Epithelial and Less Mesenchymal Cells Than Adherent Cultures: Choose Your Sjögren’s Disease Research Tool Carefully
Ting Yang¹, Abel Soto Gamez¹, Janneke Terpstra¹, Hendrika Bootsma², Arjan Vissink¹, Frans Kroese³ and Sarah Pringle³, ¹UMCG, Groningen, Netherlands, ²Department of Rheumatology and Clinical Immunology, University of Groningen, University Medical Center Groningen, Groningen, Groningen, Netherlands, ³University Medical Center Groningen, Groningen, Netherlands
Background/Purpose: The majority of the critical pieces of work probing the involvement of the salivary gland (SG) epithelium in Sjogren’s Disease (SjD) employ salivary gland…
Abstract Number: 1425 • ACR Convergence 2024
Sjögren’s Syndrome and Interstitial Lung Disease: Experience in a Collaborative Rheumatology-Pulmonology Clinic
Sonia Jiménez Barrios¹, Sandra Garrote Corral², Juan Rigual³, Carlos de La Puente Bujidos³, Maria Angeles Blazquez Canamero⁴ and Jesús Loarce³, ¹Hospital Universitario Ramón y Cajal, Madrid, Madrid, Spain, ²Hospital Universitario Ramón y Cajal, Madrid, Spain, ³Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁴Hospital Ramon y Cajal, Madrid, Madrid, Spain
Background/Purpose: Pulmonary lung disease represents the most prevalent extra-glandular manifestation in patients with Sjögren’s syndrome (SS). Notably, interstitial lung disease (ILD) stands out as the…
Abstract Number: 2287 • ACR Convergence 2024
Hydroxychloroquine and the Risk of Lymphoma Progression in Sjogren’s Disease: A Retrospective Case Control Study
Christine Xue¹, Monica Guma² and Katherine Nguyen², ¹UC San Diego, San Diego, CA, ²UC San Diego, San Diego
Background/Purpose: Sjogren's disease is an autoimmune disorder characterized by chronic lymphocytic inflammation of the salivary and lacrimal glands. Affected individuals are at heightened risk of…
Abstract Number: 2303 • ACR Convergence 2024
Type I Interferon Signature Drives Phenotypic Clusters of Sjögren’s Disease and Can Predict Systemic Evolution Among the “B-cell Active with Low Symptoms” Subgroup
Yann Nguyen¹, Maxime Beydon², Jacques-Eric Gottenberg³, Jacques MOREL⁴, Aleth Perdringer⁵, Emmanuelle Dernis⁶, Valerie Devauchelle⁷, Damien Sène⁸, Philippe Dieudé⁹, Marion couderc¹⁰, Anne-Laure Fauchais¹¹, Claire Larroche¹², Olivier Vittecoq¹³, Carine salliot¹⁴, Eric Hachulla¹⁵, Véronique Le Guern¹⁶, Xavier Mariette¹⁷, Raphaele Seror¹⁸ and Gaetane Nocturne¹⁷, ¹Université Paris Saclay, Clichy, Ile-de-France, France, ²Université Paris Saclay, Kremlin Bicetre, ³Rheumatology Department, Strasbourg University Hospital,, Strasbourg, France, ⁴CHU and University of Montpellier, Montpellier, France, ⁵CHU Rennes Univ Rennes, Rennes, France., Rennes, ⁶CH LE MANS, LE MANS, Pays de la Loire, France, ⁷UBO, Brest, France, ⁸Department of internal medicine, Centre de Compétence Maladies Rares autoimmunes et inflammatoires, Lariboisière Hospital, Université Paris Cité, Paris, Ile-de-France, France, ⁹Departement of Rheumatology, AP-HP, Bichat Hospital, Paris, France, ¹⁰CHU de Clermont-Ferrand, Clermont-Ferrand, ¹¹University Hospital of Limoges, Limoges, ¹²Avicenne University Hospital, Avicenne, France, ¹³CHU and University of Rouen, Rouen, France, ¹⁴Department of Rheumatology, Centre Hospitalier Régional d'Orléans, Orléans, France., Orléans, ¹⁵Department of Internal Medicine and clinical immunology, North-West National Reference Center for Rare Systemic Autoimmune Diseases iques et Auto-Immunes Rares du Nord-Ouest, Hôpital Claude Huriez, Université de Lille, France, Lille, France, ¹⁶APHP, Hôpital Cochin, Paris, ¹⁷Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ¹⁸Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France
Background/Purpose: Sjögren’s disease (SjD) is a heterogenous autoimmune disease, with a wide range of symptoms, from dryness, fatigue, pain, to systemic manifestations, and an increased…
Abstract Number: 2633 • ACR Convergence 2024
Multicenter Validation of a Machine Learning Foundation Model to Diagnose Sjögren’s Disease and Identify Histological Biomarkers for Disease Stratification
Julien Duquesne¹, Charlotte Claye¹, Louis Basseto¹, Michael Barnes², Elena Pontarini³, Amaya Syed², Michele Bombardieri⁴, Benjamin A. Fisher⁵, SABA NAYAR⁵, Andreas Goules⁶, Athanasios Tzioufas⁷, Loukas chatzis⁸, Wan Fai Ng⁹, Bec Scane¹⁰, Matilde Bandeira¹¹, Vasco C. Romão¹², Thierry Lazure¹³, Clovis Adam¹⁴, Xavier Mariette¹⁵, Samuel Bitoun¹⁶ and Vincent Bouget¹⁷, and NECESSITY Consortium, ¹Scienta Lab, Paris, France, ²William Harvey Research institute, Centre for Translational Bioinformatics, London, United Kingdom, ³William Harvey Research Institute, London, United Kingdom, ⁴Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ⁵University of Birmingham, Birmingham, United Kingdom, ⁶GENERAL HOSPITAL LAIKO ATHENS, Athens, Greece, ⁷LAIKO HOSPITAL, Athens, Greece, ⁸Pathophysiology Department, Athens School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, Cholargos Athens, Greece, ⁹Department of Rheumatology, Newcastle University, & HRB Clinical Research Facility, University College Cork, Newcastle upon Tyne, United Kingdom, ¹⁰Department of Rheumatology, Newcastle University, Athens, Greece, ¹¹Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, ¹²Rheumatology Department, ULS Santa Maria & Rheumatology Research Unit, Instituto Medicina Molecular, Faculty of Medicine, University of Lisbon, Lisbon, Portugal, ¹³APHP. Université Paris-Saclay, Hôpital Bicêtre, Anatomie et cytologie pathologiques, Paris, France, ¹⁴APHP. Université Paris-Saclay, Hôpital Bicêtre, Laboratoire de neuropathologie, Paris, France, ¹⁵Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ¹⁶Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin-Bicetre, France, ¹⁷Scienta Lab, Gif-sur-Yvette, France
Background/Purpose: Sjögren’s Disease (SjD) classification relies on the EULAR/ACR 2016 criteria: i) quantifying lymphocyte infiltration in labial salivary gland (LSG) biopsies, ii) autoantibody status and…
Abstract Number: 0017 • ACR Convergence 2024
Syndecan-1 Plays a Role in the Pathogenesis of Sjögren’s Syndrome by Inducing B-cell Chemotaxis Through CXCL13-heparan Sulfate Interaction
Sang Jin Lee¹, Nan Young Lee², Eun Joo Lee³, Ji Ae Jang³, Gun Woo Kim³ and Eon Jeong Nam², ¹Kyungpook National University Hospital, Daegu, Republic of Korea, ²Kyungpook National University Chilgok Hospital, Daegu, Republic of Korea, ³Daegu Fatima Hospital, Daegu, Republic of Korea
Background/Purpose: Primary Sjögren’s syndrome (pSS) is a prototypical autoimmune disorder with lymphocytic infiltration of exocrine and non-exocrine epithelia, where complex interactions between innate and adaptive…
Abstract Number: 1410 • ACR Convergence 2024
Using Social Listening to Understand the Patient Voice: The Daily Impacts of Sjögren’s Disease
Zachary Cline¹, Maurice Flurie¹, Colton Flowers¹, Enming Zhang¹, Annie Lau-Kilby², Julia Taylor², Chiara Baldini³, Ilias Alevizo², Kristina Davidson², Christopher DeFelice¹ and Maria Picone¹, ¹TREND Community, Philadelphia, PA, ²Amgen Inc., Thousand Oaks, CA, ³University of Pisa, Department of Clinical and Experimental Medicine - Rheumatology Unit, Pisa, Italy
Background/Purpose: Insights into the everyday burden and management of a disease relies on patient perspectives, and social media groups focused on specific diseases offer a…
Abstract Number: 1426 • ACR Convergence 2024
Single Cell RNA-Seq Characterization of Circulating Immune Cells in Sjogren’s Syndrome: Comparison to SLE and Rheumatoid Arhtritis
Alejandro Gomez-Gomez¹, yolanda Guillen², Paloma Vela Casasempere³, María Paula álvarez Hernández⁴, Ignacio Brana Abascal⁵, Mónica Fernández Castro⁶, Maria López Lasanta¹, José María Pego-Reigosa⁷, Carlos Marras⁸, María García-Villanueva⁹, Francisco Blanco¹⁰, Patricia Carreira¹¹, Carolina Perez-Garcia¹², Íñigo Rúa-Figueroa¹³, Hugo F Avalos bogado¹, Natalia Boix Martí¹, Eric Kirkegaard-Biosca¹⁴, iago álvarez Sáez¹⁵, Nuria Palau¹⁶, Raül Tortosa¹⁶, Jesús Tornero Molina¹⁷, Antonio Fernandez Nebro¹⁸, Jaime Calvo-Alén¹⁹, Juan Cañete²⁰, Damiana Alvarez-Errico², Ernest Choy²¹, Holger Heyn²², Antonio Julia²³, Sara Marsal barril¹ and Jose Luis Andreu²⁴, and on behalf of SSAD and DocTIS consortia, ¹Hospital Universitari Vall d´Hebron, Rheumatology, Barcelona, Spain, ²Imidomics, Inc, Barcelona, Spain, ³Hospital General Universitario de Alicante , Rheumatology, Alicante, Spain, ⁴Hospital universitario de la Princesa. IIS-Princesa, Rheumatology, Madrid, Madrid, Spain, ⁵Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ⁶Hospital Universitario Puerta de Hierro Majadahonda., Madrid, Madrid, Spain, ⁷Galicia Health Service (SERGAS), Vigo, Spain, ⁸Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Murcia, Spain, ⁹Hospital Ramón y Cajal, MADRID, Madrid, Spain, ¹⁰Complejo Hospitalario Universitario de A Coruña , Rheumatology, A Coruña, Spain, ¹¹Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ¹²Hospital del Mar, Barcelona, Spain, ¹³Department of Rheumatology, Hospital Universitario Doctor Negrín, Las Palmas de Gran Canaria, Las Palmas GC, Spain, ¹⁴Hospital Universitari Vall d´Hebron, Ophtalmology, Barcelona, Spain, ¹⁵Hospital Universitari Vall d´Hebron, Maxillofacial Surgery, Barcelona, Spain, ¹⁶Vall d´Hebron Hospital Research Institute, Rheumatology, Barcelona, Spain, ¹⁷Sociedad Española de Reumatologia, Rheumatology, Madrid, Spain, ¹⁸Hospital Regional Universitario Carlos Haya , Rheumatology, Málaga, Spain, ¹⁹Department of Rheumatology, Hospital Araba, Vitoria, Pais Vasco, Spain, ²⁰Hospital Clinic an IDIBAPS, Barcelona, Spain, ²¹Cardiff University School of Medicine, Cardiff, United Kingdom, ²²Centre for Genomic Regulation (CNAG-CRG), National Centre for Genomic Analysis, Barcelona, Spain, ²³Vall d'Hebron Hospital Research Institute, Barcelona, Spain, ²⁴Hospital Universitario Puerta de Hierro Majadahonda., Majadahonda, Spain
Background/Purpose: Primary Sjögren’s Syndrome (pSS) shares with SLE and RA features including their predominance in women, immunological characteristics and genetic risk background. Hence, to dissect…
Abstract Number: 2288 • ACR Convergence 2024
Interferon Gamma Signaling Is Associated with Development of Extraglandular Manifestations in Sjögren’s Disease
Hiroyuki Nakamura¹, Koki Nakamura¹, Hidenori Amaike¹, Ken Nagahata¹, Masatoshi Kanda² and Hiroki Takahashi¹, ¹Sapporo Medical University, Sapporo, Japan, ²Department of Rheumatology and Clinical Immunology, Sapporo Medical University, Sapporo, Japan, Sapporo, Japan
Background/Purpose: Sjögren’s disease (SjD) is an autoimmune disease that primarily affects salivary and lacrimal glands. Some patients with SjD develop various extraglandular manifestations (EGM), such…
Abstract Number: 2304 • ACR Convergence 2024
Differential Diagnosis of Sjogren’s vs Non-Sjogren’s Dry Eye
Esen Akpek¹, Ian Saldanha², Pineal Bareamichael² and Michael Lin³, ¹Wilmer Eye Institute, JHU, Baltimore, MD, ²Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, ³Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dry Eye Disease (DED) is a common multifactorial condition that significantly impacts patient quality of life. The etiology of DED is complex, involving tear…
Abstract Number: 2634 • ACR Convergence 2024
Transcriptomic Stratification Predicts Response to Rituximab, Abatacept or the Association of Hydroxychloroquine and Leflunomide in 3 Randomized Controlled Clinical Trials in Sjögren’s Disease
Baptiste Chevet¹, Valerie Devauchelle², Elena Pontarini³, Valentin Baloche⁴, Michele Bombardieri⁵, Simon Bowman⁶, Michael Barnes⁷, Antoine Sreih⁸, Jinqi Liu⁸, Sheila Kelly⁹, Antonia Christodoulou⁸, Hussain Badani¹⁰, Philippe Moigeon¹¹, Laurence LAIGLE¹², Perrine Soret¹³, Christelle Le dantec¹⁴, Jacques-Olivier Pers¹⁵, Marta Alarcon-Riquelme¹⁶, Guillermo Barturen¹⁷, Xavier Mariette¹⁸, Joel Van Roon¹⁹, Raphaele Seror²⁰, Gaetane Nocturne¹⁸, Divi Cornec²¹ and Nathan Foulquier¹⁴, and PRECSEADS Clinical Consortium and NECESSITY consortium, ¹University Hospital of Brest, Brest, France, ²UBO, Brest, France, ³William Harvey Research Institute, London, United Kingdom, ⁴University Medical Center, Utrecht, Utrecht, Netherlands, ⁵Centre for Experimental Medicine and Rheumatology, The William Harvey Research Institute, Queen Mary University of London, London, United Kingdom, ⁶Department of Rheumatology, University Hospital Birmingham, Birmingham, United Kingdom, ⁷William Harvey Research institute, Centre for Translational Bioinformatics, London, United Kingdom, ⁸Bristol Myers Squibb, Princeton, NJ, ⁹Bristol Myers Squibb, Doylestown, PA, ¹⁰Bristol Myers Squibb, Lawrence Township, NJ, ¹¹Servier Laboratories, France, Gif sur Yvette, France, ¹²Servier Laboratories, France, SURESNES, France, ¹³Servier, Paris-Saclay, Paris, Ile-de-France, France, ¹⁴LBAI. UMR 1227, University of Brest, Brest, France, ¹⁵University of Brest, Brest, France, ¹⁶Fundación Progreso y Salud, Andalusian Government, Granada, Spain, ¹⁷Center for Genomics and Oncological Research (GENYO), Andalusia, Spain, ¹⁸Service de Rhumatologie, Hôpital Bicêtre, AP-HP, Le Kremlin Bicetre, France, ¹⁹University Medical Center Utrecht, Utrecht, Netherlands, ²⁰Service de Rhumatologie, Hôpital Bicêtre, AP-HP, le Kremlin Bicetre, Ile-de-France, France, ²¹Service de Rhumatologie, CHU de Brest, Brest, France
Background/Purpose: Sjögren’s disease (SjD) is a clinically and biologically heterogeneous disease. To date, no phase-III trial showed efficacy in reducing the symptoms or systemic activity…
Abstract Number: 0152 • ACR Convergence 2024
Hydroxychloroquine and Chloroquine Retinopathy in Hispanic Patients with Rheumatic Diseases
Janett Riega Torres¹, Karina Palomo-Arnaud², Gabriel Figueroa-Parra¹, Fernando Morales Wong¹, Jesús Hernán González Cortés¹, Jesus Mohamed Hamsho¹, Jorge Esquivel-Valerio¹, Dionicio Galarza-Delgado³ and Karim Mohamed Noriega¹, ¹Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ²Division of Rheumatology, University Hospital "Dr. Jose Eleuterio Gonzalez", Universidad Autonoma de Nuevo Leon, San Nicolás de los Garza, Mexico, ³UANL Hospital Universitario, Monterrey, Nuevo León, Mexico
Background/Purpose: Antimalarial drugs like hydroxychloroquine (HCQ) and chloroquine (CQ) are among the most frequently prescribed medications in Rheumatology. Retinal toxicity is an unwanted side effect…
Abstract Number: 1411 • ACR Convergence 2024
Impact of Patient and Physician Alignment on Sjögren’s Disease Severity, a Real-World Survey on Patients’ Clinical Outcomes and Health-Related Quality of Life
Wan Fai Ng¹, Coralie Bouillot², NICOLA MASSEY³, Megan Hughes³, Victoria Barton³, Giorgio Castellano³, Ana Barat⁴, Gayle Kenney⁵ and Jessica Marvel⁶, ¹Department of Rheumatology, Newcastle University, & HRB Clinical Research Facility, University College Cork, Newcastle upon Tyne, United Kingdom, ²Sjögren Europe, Switzerland, Switzerland, ³ADELPHI REAL WORLD, BOLLINGTON, United Kingdom, ⁴Novartis Ireland Ltd, Dublin, Ireland, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis, East Hanover, NJ
Background/Purpose: Sjögren’s disease (SjD) has a high disease burden in affected patients, with no licensed treatments currently available. The Clinical EULAR Sjögren’s syndrome disease activity…
Abstract Number: 1427 • ACR Convergence 2024
Observed and Simulated Pharmacokinetics and Pharmacodynamics of Nipocalimab, a Fully Human FcRn Blocking Monoclonal Antibody, in Adults with Sjögren’s Disease: Results from a Phase 2, Multicenter, Randomized, Placebo-controlled, Double-blind Study
Sophia G. Liva¹, fudan Zheng¹, Jocelyn H. Leu², Kathy Sivils³, Keying Ma¹, He Li⁴, Steven Leonardo⁵, Kim Lo¹, Jada Idokogi¹, Kim Campbell¹ and Jonathan J. Hubbard¹, ¹Janssen Research & Development, LLC, a Johnson & Johnson Company, Spring House, PA, ²Janssen Research & Development, LLC, a Johnson & Johnson company, Spring House, PA, PA, ³Johnson & Johnson Innovative Medicine, Edmond, OK, ⁴Janssen Research & Development, LLC, Therapeutics Discovery, Spring House, PA, ⁵Janssen Research & Development, LLC, a Johnson & Johnson Company, Cambridge, MA
Background/Purpose: Sjögren’s disease (SjD) is a chronic, progressive autoimmune disease characterized by aberrant B lymphocyte activity, elevated IgG production, and the presence of IgG autoantibodies…
Abstract Number: 2289 • ACR Convergence 2024
Associations Between Protein Quantitative Trait Loci and Risk of Primary Sjögren’s Syndrome: A Mendelian Randomization Study
Benjamin Zuckerman¹, Alasdair Warwick², art Schuermans³, Mark Gibson⁴, Ioasaf Karafotias⁵, Zijing Yang¹, Carine moezinia⁶, Mark Russell⁷, Chris Wincup⁸, James Galloway⁹ and Sizheng Zhao¹⁰, ¹King's College London, London, England, United Kingdom, ²University college London, London, United Kingdom, ³KU Leuven, Leuven, Belgium, ⁴King's College London, Newmarket, United Kingdom, ⁵King's College London, London, United Kingdom, ⁶univerity college hospital, London, United Kingdom, ⁷King's College London, London, United Kingdom, ⁸King's College Hospital, London, United Kingdom, ⁹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ¹⁰Centre for Musculoskeletal Research, The University of Manchester, Liverpool, United Kingdom
Background/Purpose: The pathophysiology of primary Sjögren’s disease involves the interaction of genetic, epigenetic, and environmental factors. With limited treatment options for severe disease, a detailed understanding…

1
2
3
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.